Yinao Capsules Combined with Memantine Hydrochloride in the Treatment of Alzheimer’s Disease in the Elderly

Jian Zhao; Xuelian Jia

doi:10.26689/ijgpn.v3i4.13206

Jian Zhao Comprehensive Internal Medicine Outpatient Department, Second People’s Hospital of Fujian University of Traditional Chinese Medicine, Fuzhou 350000, Fujian, China
Xuelian Jia Comprehensive Internal Medicine Outpatient Department, Second People’s Hospital of Fujian University of Traditional Chinese Medicine, Fuzhou 350000, Fujian, China

DOI: https://doi.org/10.26689/ijgpn.v3i4.13206

Keywords: Alzheimer’s disease dementia in the elderly, Yinao capsule, Memantine hydrochloride, Cognitive function, Quality of life

Abstract

Objective: To investigate the clinical efficacy of Yinao capsule combined with memantine hydrochloride in the treatment of Alzheimer’s disease (AD) in the elderly, and to analyze its effects on cognitive function and quality of life of patients. Methods: A total of 84 elderly AD patients admitted to the hospital from June 2022 to June 2023 were randomly divided into an observation group (42 cases, Yinao capsule combined with memantine hydrochloride) and a control group (42 cases, memantine hydrochloride monotherapy), both of which were treated for 3 months. The Mini-Intelligent Mental State Scale (MMSE) was used to evaluate cognitive function, and the Quality of Life Scale for Alzheimer’s Patients (QOL-AD) was used to evaluate the quality of life. Results: Before treatment, there was no significant difference in the MMSE AND QOL-AD scores between the two groups (P>0.05). After 3 months of treatment, the MMSE AND QOL-AD scores of both groups were significantly higher than those before treatment (both P<0.001), and the MMSE (24.70±3.70 points) and QOL-AD (31.60±3.59 points) scores in the observation group were significantly higher than those in the control group (21.24±3.33 points) and (28.44±3.26 points), both P<0.001. There were no serious adverse reactions in either group. Conclusion: Yinao capsule combined with memantine hydrochloride can significantly improve cognitive function and quality of life in elderly AD patients, and the efficacy is better than memantine hydrochloride monotherapy, and the safety is good.

References

Alzheimer’s Association 2023, 2023 Alzheimer’s Disease Facts and Figures. Alzheimer’s Dement, 19(4): 1598–1695.

Xie Y, A Vision for Treating Alzheimer’s Disease. Theoretical and Natural Science, 4(1): 698–702.

Badawoud AM, AlQadheeb YK, AlZahrani SS, et al., 2023, The Level of Burden among Caregivers of Patients with Alzheimer’s Disease in Saudi Arabia. International Journal of Environmental Research and Public Health, 20(4): 2864.

Li J, Haj Ebrahimi A, Ali AB, 2024, Advances in Therapeutics to Alleviate Cognitive Decline and Neuropsychiatric Symptoms of Alzheimer’s Disease. International Journal of Molecular Sciences, 25(10): 5169.

Al-hussaniy HA, Alkhafaje Z, Altamimi ZS, et al., 2023, Memantine and its Role in Parkinsonism, Seizure, Depression, Migraine Headache, and Alzheimer’s Disease. PHARMACIA, 70(2): 291–297.

Althobaiti YS, 2020, Development of Memantine as a Drug for Alzheimer’s Disease: A Review of Preclinical and Clinical Studies. Tropical Journal of Pharmaceutical Research, 19(7): 1535–1540.

Yang Y, Wang L, Zhang C, et al., 2022, Ginsenoside Rg1 Improves Alzheimer’s Disease by Regulating Oxidative Stress, Apoptosis, and Neuroinflammation through Wnt/GSK-3β/β-catenin Signaling Pathway. Chemical Biology & Drug Design, 99(6): 884–896.

Liu Y, Gao Y, Li KX, et al., 2019, Pharmacokinetics and Acetylcholine Releasing Effects of Ginsenoside Rg1 in Hippocampus of Beta-amyloid Model Rats. Journal of Asian Natural Products Research, 21(8): 772–781.

Quan Q, Wang J, Li X, et al., 2013, Ginsenoside Rg1 Decreases Aβ(1-42) Level by Upregulating PPARγ and IDE Expression in the Hippocampus of a Rat Model of Alzheimer’s Disease. PloS one, 8(3): e59155.

Li F, Wu X, Li J, et al., 2016, Ginsenoside Rg1 Ameliorates Hippocampal Long-term Potentiation and Memory in an Alzheimer’s Disease Model. Molecular Medicine Reports, 13(6): 4904–4910.

Sun Y, Yang Y, Liu S, et al., 2022, New Therapeutic Approaches to and Mechanisms of Ginsenoside Rg1 against Neurological Diseases. Cells, 11(16): 2529.

Zhang Y, Li H, Song L, et al., 2021, Polysaccharide from Ganoderma Lucidum Ameliorates Cognitive Impairment by Regulating the Inflammation of the Brain-Liver Axis in Rats. Food & function, 12(15): 6900–6914.

Yu SP, Jiang MQ, Shim SS, et al., 2023, Extrasynaptic NMDA Receptors in Acute and Chronic Excitotoxicity: Implications for Preventive Treatments of Ischemic Stroke and Late-onset Alzheimer’s Disease. Molecular neurodegeneration, 18(1): 43.

Marotta G, Basagni F, Rosini M, et al., 2020, Memantine Derivatives as Multitarget Agents in Alzheimer’s Disease. Molecules (Basel, Switzerland): 25(17): 4005.

Liang HY, Zhang PP, Zhang XL, et al., 2021, Preclinical Systematic Review of Ginsenoside Rg1 for Cognitive Impairment in Alzheimer’s Disease. Aging, 13(5): 7549–7569.

Wang N, Yang J, Chen R, et al., 2023, Ginsenoside Rg1 Ameliorates Alzheimer’s Disease Pathology via Restoring Mitophagy. Journal of Ginseng Research, 47(3): 448–457.

Quan Q, Ma X, Li M, et al., 2023, Ginsenoside Rg1 Promotes β amyloid Peptide Degradation through Inhibition of the ERK/PPARγ Phosphorylation Pathway in an Alzheimer’s Disease Neuronal Model. Experimental and Therapeutic Medicine, 27(1): 31.

Li X, Huang L, Kong L, et al., 2023, Ginsenoside Rg1 Alleviates Learning and Memory Impairments and Aβ Disposition through Inhibiting NLRP1 Inflammasome and Autophagy Dysfunction in APP/PS1 Mice. Molecular Medicine Reports, 27(1): 6.

Qin Y, Zhao Y, Hu X, et al., 2024, Ganoderma Lucidum Spore Extract Improves Sleep Disturbances in a Rat Model of Sporadic Alzheimer’s Disease. Frontiers in Pharmacology, 2024(15): 1390294.

Zhao Y, Qin Y, Hu X, et al., 2024, Sporoderm-removed Ganoderma Lucidum Spores Ameliorated Early Depression-like Behavior in a Rat Model of Sporadic Alzheimer’s Disease. Frontiers in Pharmacology, 2024(15): 1406127.

Ahmad F, Singh G, Soni H, et al., 2023, Identification of Potential Neuroprotective Compound from Ganoderma Lucidum Extract Targeting Microtubule Affinity Regulation Kinase 4 Involved in Alzheimer’s Disease through Molecular Dynamics Simulation and MMGBSA. Aging Med (Milton): 6(2): 144–154.

Chen XJ, Deng Z, Zhang LL, et al., 2024, Therapeutic Potential of the Medicinal Mushroom Ganoderma Lucidum against Alzheimer’s Disease. Biomedicine & Pharmacotherapy, 2024(172): 116222.

Liu S, Chen W, Zhao Y, et al., 2023, Research Progress on Effects of Ginsenoside Rg2 and Rh1 on Nervous System and Related Mechanisms. Molecules (Basel, Switzerland): 28(23): 7935.

Song X, Wang L, Fan D, 2022, Insights into Recent Studies on Biotransformation and Pharmacological Activities of Ginsenoside Rd. Biomolecules, 12(4): 512.

Malík M, Tlustoš P, 2022, Nootropics as Cognitive Enhancers: Types, Dosage and Side Effects of Smart Drugs. Nutrients, 14(16): 3367.

Li T, Chen J, Xie Z, et al., 2025, Ginsenoside Ro Ameliorates Cognitive Impairment and Neuroinflammation in APP/PS1 Mice via the IBA1/GFAP-MAPK Signaling Pathway. Frontiers in Pharmacology, 2025(16): 1528590.

Xu Q, Cui F, Li X, et al., 2023, Dangshen Huangjiu Prevents Gastric Mucosal Injury and Inhibits Akt/NF-κB Pathway. Food & Function, 14(17): 7897–7911.

He RP, Jin Z, Ma RY, et al., 2020, Network Pharmacology Unveils Spleen-Fortifying Effect of Codonopsis Radix on Different Gastric Diseases Based on Theory of “Same Treatment for Different Diseases” in Traditional Chinese Medicine. Chinese Herbal Medicines, 13(2): 189–201.

Zhao Y, Qin Y, Hu X, et al., 2024, Sporoderm-removed Ganoderma Lucidum Spores Ameliorated Early Depression-like Behavior in a Rat Model of Sporadic Alzheimer’s Disease. Frontiers in Pharmacology, 2024(15): 1406127.